Amikacin sulfate is released for downstream dosage-form manufacture only after the lot assay, water content, residual solvent profile, and elemental impurity panel establish a potency-corrected mass balance. The compendial potency window of 674 µg/mg to 786 µg/mg on dried basis means that two sites purchasing the same nominal “active” quantity may differ by more than 14% in actual amikacin base delivered if the sulfate salt is weighed without correction. The downstream uses are therefore not a single formulation family; they are separated by sterility assurance level, particle-size control, pH latitude, terminal heat exposure, and route-specific impurity risk.

When Amikacin Sulfate Enters an ISO 7 Aseptic Filling Line

Amikacin sulfate received for sterile injectable manufacture is first subjected to full monograph release testing per USP Amikacin Sulfate. The assay is expressed as amikacin base, and the exact lot potency becomes the basis for the salt correction calculation: API input in milligrams equals the labeled base concentration multiplied by 1000 and divided by lot potency in µg/mg. For a 50 mg/mL product this yields an input range of 63.6 mg to 74.2 mg of amikacin sulfate per milliliter before drying correction; for a 250 mg/mL product the corresponding range is 318.1 mg to 371.0 mg per milliliter. On production-scale compounding skids, batch-to-batch movement from 690 µg/mg to 730 µg/mg changes the sulfate input by approximately 5–6%, requiring recalculation and balance verification for every campaign. The solution is adjusted with 1 N sulfuric acid or sodium hydroxide to hold within pH 3.5–5.5; pH excursions above 6.0 during compounding accelerate the formation of amikacin-related amine degradation products and should trigger rework or rejection.

Process transfer from the compounding vessel to the filling line uses 316L stainless steel with electropolished product-contact surfaces. Two-stage filtration through a 0.45 µm PVDF prefilter and a 0.22 µm PVDF sterilizing filter is performed at 20–25 °C and ≤1.5 bar differential pressure. Filter blinding has been observed when the bulk solution is filtered before complete dissolution or when low-pH precipitation produces fine sulfate aggregates; the corrective action is to maintain pH above 3.5 and to monitor differential pressure across the prefilter. Filling into 2 mL, 5 mL, or 10 mL Type I glass vials is conducted under Grade A conditions with RABS or isolator per EU GMP Annex 1 and ISO 14644-1:2015. Finished product is tested for sterility per USP <71>, bacterial endotoxins per USP <85>, particulate matter per USP <788>, visible particulates per USP <790>, and elemental impurities per ICH Q3D. Terminal product types include 50 mg/mL and 250 mg/mL single-dose vials, pharmacy bulk packs, and diluted intravenous infusion bags at 0.5 mg/mL to 5.0 mg/mL in 0.9% sodium chloride or 5% dextrose.

Liposomal amikacin inhalation suspension is manufactured to a labeled strength of 70 mg/mL amikacin base in a sterile, lipid-encapsulated form; the approved finished vial contains 590 mg amikacin per 8.4 mL. The formulation route is governed by the approved product label rather than a general monograph, and the manufacturing sequence includes lipid film hydration or ethanol injection into an aqueous phase containing amikacin sulfate, followed by high-shear homogenization and sequential extrusion through polycarbonate membranes to control liposome mean diameter to approximately 200–300 nm. Free amikacin is separated from encapsulated drug by ultrafiltration or diafiltration, and the sulfate counterion is adjusted so that the final drug load is expressed as amikacin base. If the input lot assay potency is lower than 700 µg/mg, the salt correction increases proportionally and the post-diafiltration assay must be repeated. The suspension is buffered to a pH below 7.0 to limit lipid hydrolysis, and osmolality is typically adjusted to 300–450 mOsm/kg with sodium chloride. Sterile filtration through 0.22 µm membranes is generally not feasible for a 200–300 nm liposome population, so upstream particulate control and aseptic process simulation become critical rather than optional.

Aerodynamic performance is not inferred from liposome size alone. The suspension is aerosolized with the designated nebulizer system, and delivered dose plus fine particle fraction are tested by cascade impaction per USP <601> or Ph. Eur. 2.9.44, with aerodynamic mass median diameter in the 4.0–5.0 µm range for the emitted droplet population. Terminal product remains a single-use glass vial of sterile liposomal suspension; it is not terminally sterilized after filling, so aseptic processing under EU GMP Annex 1 and ISO 14644-1:2015 Class A conditions is required. The compliance package must also include sterility per USP <71>, bacterial endotoxins per USP <85>, and elemental impurities per ICH Q3D.

What Limits Sterility Assurance in Compounded Fortified Ophthalmic Amikacin 25 mg/mL?

Compounded fortified ophthalmic amikacin 25 mg/mL is prepared in hospital and 503B outsourcing facilities for bacterial keratitis when commercial aminoglycoside eye drops are unavailable or resistant. The addition ratio is potency-corrected: for a lot assay of 700 µg/mg, 35.7 mg of amikacin sulfate per milliliter delivers 25 mg of amikacin base; if the lot potency falls to 674 µg/mg, input rises to 37.1 mg/mL. The drug is dissolved in sterile water for injection or balanced salt solution, and tonicity is adjusted to 250–350 mOsm/kg with sodium chloride; pH is held at 6.0–7.0 to balance amikacin stability against ocular tolerability. Processing is performed in an ISO 5 laminar airflow hood within an ISO 7 buffer room per USP <797>. The solution is passed through a 0.22 µm PVDF syringe filter into sterile amber LDPE or glass ophthalmic dropper bottles. No terminal sterilization step is used, so the maximum beyond-use date is assigned from the compounded sterile preparation risk level and stability data; refrigerated storage at 2–8 °C and protection from light are required. Finished product types include 5 mL and 10 mL fortified ophthalmic drops. Repeated use beyond the annotated beyond-use date is an infection risk, and any visible precipitation or pH drift above 7.0 requires destruction of the batch.

Oral amikacin sulfate capsules for selective digestive decontamination are compounded rather than manufactured under a harmonized commercial monograph; published data for this specific configuration is limited, and the route is exploited only because aminoglycoside absorption from the intact gastrointestinal tract is below 1% of an oral dose. Typical compounding records use amikacin sulfate equivalent to 100–500 mg amikacin base per capsule or per oral suspension unit, but institutional protocols vary. The input mass must be corrected for the exact lot potency and for moisture content if the powder is stored at RH >60% before weighing. Because amikacin sulfate is hygroscopic, pre-drying at 40–50 °C under vacuum is required only when the lot exceeds the water specification; excipient selection is restricted to lactose monohydrate or mannitol in dry powder blends to avoid Maillard degradation. Capsule filling on a dosator or tamping-pin machine requires particle-size control; amikacin sulfate may be milled and sieved through 80-mesh (177 µm) or 120-mesh (125 µm) screens to improve content uniformity per USP <905>. Dissolution testing per USP <711> is of limited physiological relevance for local gut action but is still performed for batch release. Non-sterile compounding requires USP <795> or pharmaceutical GMP compliance, while clinical use as a non-absorbed local anti-infective remains institution-specific.

Antibiotic-Loaded PMMA Bone Cement: Release Kinetics and Mixing Constraints

Amikacin sulfate is incorporated into poly(methyl methacrylate) bone cement at reported loadings of 1.0 g to 2.5 g per 40 g of PMMA powder; loadings above 2.5 g per 40 g powder are associated with reduced compressive and bending strength and should not be assumed to meet ISO 5833:2002 mechanical minima. The cement powder containing amikacin sulfate is mixed with liquid methyl methacrylate monomer under vacuum in a ≤0.1 bar mixing chamber to reduce porosity; the monomer-to-powder ratio remains product-specific, and the working time is verified on a rheometer because the addition of an ionic sulfate changes the polymerization exotherm and setting profile. The exotherm peak in a 40 g mix can exceed 70 °C, but the time at elevated temperature is short; amikacin sulfate is selected because aminoglycosides retain activity after short exposure to the curing exotherm. Release kinetics from PMMA are biphasic, with an initial surface burst followed by diffusion-limited elution; batch testing includes compressive strength per ISO 5833:2002 or ASTM F451-16 for acrylic bone cement, plus antibiotic elution by high-performance liquid chromatography to confirm the delivered dose. Terminal product types include pre-filled PMMA powder vials with separate monomer ampoules, articulating spacers, and antibiotic-loaded cement beads for revision arthroplasty. The device-drug combination pathway requires coordination with 21 CFR 210/211 and device quality-system requirements; the amikacin sulfate component must still meet the pharmacopeial monograph.

Peritoneal dialysis admixture compounding begins with a patient-specific mg/kg order rather than a fixed percentage formula; the amikacin sulfate input is calculated per dwell bag. For a 2 L dextrose-based dialysate bag and a target 25 mg/L amikacin base concentration, the required amikacin base is 50 mg, which at a lot potency of 700 µg/mg corresponds to 71.4 mg of amikacin sulfate; if the lot potency is 674 µg/mg, the input becomes 74.2 mg. The addition is performed by aseptic transfer of a preserved free solution or the injectable product into a peritoneal dialysis bag in an ISO 5 hood per USP <797>; the bag is mixed by inversion 10–12 times and visually inspected for precipitate. Amikacin is stable in dextrose-based peritoneal dialysis solutions for 24 h at room temperature; higher dwell temperatures and pH drift above 6.5 may reduce assay, so prolonged storage is not recommended. The terminal dosage form is a single-use peritoneal dialysis bag of 1.5 L, 2.0 L, or 2.5 L containing 1.5%, 2.5%, or 4.25% dextrose and the added amikacin sulfate solution. Sterility and endotoxin requirements follow USP <71> and USP <85>; because no terminal sterilization is applied after admixture, any deviation from aseptic technique invalidates the bag.

Topical Hydrogel Compounding Remains Limited by Water Activity Controls

Topical amikacin hydrogel is compounded for infected burn wounds and wound-bed colonization; no harmonized commercial monograph exists, and published data for this specific configuration is limited. A common addition ratio is 1.0% w/w amikacin base in a poloxamer 407 gel or hydroxyethylcellulose gel; for a 100 g batch, the API input is 1.0 g amikacin base corrected by the lot potency. The manufacturing process is cold hydration of the gelling polymer under aseptic conditions, followed by slow addition of a concentrated amikacin sulfate solution and pH adjustment to 6.0–7.0; the product is filled into 30 g or 50 g sterile ointment tubes or amber glass jars. Because wound use requires sterility, USP <797> sterile compounding standards apply rather than USP <795> nonsterile compounding; the finished gel is tested for microbial limits and, where required, antimicrobial effectiveness per USP <51>. Operational boundaries include avoiding strong oxidizers and anionic thickeners that may precipitate the sulfate salt; aqueous formulations should not be exposed to pH above 7.5 during manufacture or storage.